Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Etavopivat in Participants With Hepatic Impairment
NCT06336018Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of etavopivat in sickle cell disease (SCD) (5 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the plasma concentration-time curve from 0 hours to infinity at Day 9 and Maximum observed plasma concentration at Day 9. Started May 2024; status: completed.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06336018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336018.